SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PF-05221304

Item No. 36856

CAS Registry No.:	1370448-25-1
Formal Name:	4-[6-methoxy-4-[[1,4,6,7-tetrahydro-1-(1-methylethyl)-7-oxospiro[5H-indazole-5,4′-piperidin]-1′-yl]carbonyl]-2-pyridinyl]-benzoic acid
Synonym:	Clesacostat
MF:	$C_{28}H_{30}N_4O_5$
FW:	502.6
Purity:	≥98%
UV/Vis.:	λ_{max}: 255, 311 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-05221304 is supplied as a solid. A stock solution may be made by dissolving the PF-05221304 in the solvent of choice, which should be purged with an inert gas. PF-05221304 is soluble in DMSO.

Description

PF-05221304 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC_{50}s = 12.4 and 8.7 nM, respectively).[1] It inhibits *de novo* lipid synthesis (IC_{50} = 61 nM) and increases fatty acid oxidation in primary human hepatocytes. PF-05221304 reduces the accumulation of triglycerides composed of *de novo*-derived fatty acids but not dietary essential fatty acids in primary human hepatocytes. *In vivo*, PF-05221304 (10 and 100 mg/kg) reduces hepatic malonyl-CoA production and *de novo* lipogenesis in rats. It reduces hepatic fibrosis, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and triglyceride accumulation in a rat model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).

Reference

1. Ross, T.T., Crowley, C., Kelly, K.L., *et al.* Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems. *Cell. Mol. Gastroenterol. Hepatol.* **10(4),** 829-851 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM